慢性淋巴细胞白血病和里氏转化患者中ARI-0001 CART19细胞的研究结果。
Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation.
作者信息
Ortiz-Maldonado Valentín, Frigola Gerard, Español-Rego Marta, Balagué Olga, Martínez-Cibrián Nuria, Magnano Laura, Giné Eva, Pascal Mariona, Correa Juan G, Martínez-Roca Alexandra, Cid Joan, Lozano Miquel, Villamor Neus, Benítez-Ribas Daniel, Esteve Jordi, López-Guillermo Armando, Campo Elías, Urbano-Ispizua Álvaro, Juan Manel, Delgado Julio
机构信息
Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain.
Oncology and Hematology, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
出版信息
Front Oncol. 2022 Jan 31;12:828471. doi: 10.3389/fonc.2022.828471. eCollection 2022.
CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter's transformation (RT). One patient with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5% grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high-risk CLL or RT.
嵌合抗原受体T细胞（CART19）疗法正逐渐成为慢性淋巴细胞白血病（CLL）患者的一种替代治疗方法。在此，我们报告了连续9例接受ARI-0001 CART19细胞治疗的CLL患者的治疗结果，其中6例发生Richter转化（RT）。1例发生RT的患者未接受任何治疗。细胞因子释放综合征发生率为87.5%（≥3级为12.5%）。未观察到任何患者出现神经毒性。所有患者均出现绝对B细胞发育不全，7例（87.5%）患者对治疗有反应。中位随访时间为5.6个月，2例发生RT的患者出现CD19阴性复发。总之，ARI-0001细胞疗法对于高危CLL或RT患者是可行、安全且有效的。
Zotero 插件